UAB30 / UAB University - Birmingham 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  UAB30 - UAB University / Birmingham
    Biomarker, Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov) -  Dec 27, 2023   
    P1/2,  N=0, Withdrawn, 
    Our data also show the critical role of miRs responsive to UAB30 treatment in cancer chemoprevention. N=84 --> 0 | Trial completion date: Aug 2025 --> Aug 2023 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2024 --> Aug 2023
  • ||||||||||  UAB30 - UAB University / Birmingham
    Biomarker, Trial completion date, Trial primary completion date, IO biomarker:  A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov) -  Aug 30, 2023   
    P1/2,  N=84, Recruiting, 
    Conclusions The RXR agonists have an immunostimulatory role with plasmid cancer vaccines, but further modification of the immune environment may be needed for prevention vaccines. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
  • ||||||||||  UAB30 - UAB University / Birmingham
    Epigenetic mechanism underlying pathogenesis of skin photo-damage and actinic keratoses (Section 36; Poster Board #5) -  Mar 14, 2023 - Abstract #AACR2023AACR_3322;    
    9cUAB30 treatment attenuates growth of human SCC xenograft tumors in highly immune-suppressed mice, a response which was significantly more profound when the drug was administered with a survivin inhibitor, LQZ-7I. These translational studies demonstrate that UVB-induced cutaneous BRD4 drives AK pathogenesis and their progression to invasive SCCs.
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial completion date:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  Feb 8, 2023   
    P1,  N=39, Active, not recruiting, 
    These translational studies demonstrate that UVB-induced cutaneous BRD4 drives AK pathogenesis and their progression to invasive SCCs. Trial completion date: Feb 2023 --> Jun 2023
  • ||||||||||  AZD1208 / AstraZeneca, UAB30 - UAB University / Birmingham
    PIM Kinase Inhibition Results in Neuroblastoma Differentiation (H0100: Section on Surgery) -  Nov 10, 2022 - Abstract #AAPNCE2022AAP_NCE_1748;    
    These findings are potentially mediated through increased HOXC9. These data support the need for further studies of the role of PIM kinase inhibition as a therapeutic strategy to improve RA-induced differentiation, potentially mitigating disease relapse in high risk neuroblastoma.
  • ||||||||||  UAB30 - UAB University / Birmingham
    Biomarker, Trial completion date, Trial primary completion date, IO biomarker:  A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov) -  Aug 31, 2022   
    P1/2,  N=84, Recruiting, 
    These data support the need for further studies of the role of PIM kinase inhibition as a therapeutic strategy to improve RA-induced differentiation, potentially mitigating disease relapse in high risk neuroblastoma. Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  UAB30 - UAB University / Birmingham
    Enrollment closed, Trial primary completion date:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  Jun 13, 2022   
    P1,  N=38, Active, not recruiting, 
    Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Jun 2022
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial completion date, Trial primary completion date:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  Feb 18, 2022   
    P1,  N=41, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Jun 2022 Trial completion date: Feb 2022 --> Dec 2022 | Trial primary completion date: Feb 2022 --> Dec 2022
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial primary completion date:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  May 14, 2021   
    P1,  N=45, Recruiting, 
    6-Me decreased oncogenicity and reduced cancer cell stemness of neuroblastoma PDXs, warranting further exploration of 6-Me as potential novel therapy for neuroblastoma. Trial primary completion date: Jul 2021 --> Feb 2022
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial primary completion date:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  Feb 23, 2021   
    P1,  N=45, Recruiting, 
    These data indicate that RXR agonists have an immunostimulatory role with multi-antigen cancer vaccines and may augment the anti-tumor activity of vaccines. Trial primary completion date: Feb 2022 --> Apr 2021
  • ||||||||||  UAB30 - UAB University / Birmingham
    Enrollment open:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  May 20, 2020   
    P1,  N=40, Recruiting, 
    These results provide evidence that UAB30 decreased tumorigenicity and cancer cell stemness in neuroblastoma PDXs, warranting further exploration as therapy for high-risk neuroblastoma. Suspended --> Recruiting
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Clinical, Journal:  Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN. (Pubmed Central) -  Mar 31, 2020   
    These methods have general applicability beyond this NEt-TMN case study, and can be employed to characterize and biologically evaluate other putative RXR agonists (rexinoids), and benchmarked against perhaps the most common rexinoid known as bexarotene (Bex), a drug awarded FDA approval for the treatment of cutaneous T-cell lymphoma in 1999 but that is also prescribed for non-small cell lung cancer and continues to be explored in multiple human cancer types...Notable examples of potent rexinoids in addition to Bex and NEt-TMN include CD3254, LGD100268, and 9-cis-UAB30...In addition, a second, more sensitive assay is also detailed that utilizes activation of RXR-RXR homodimers in the context of a mammalian two-hybrid (M2H) luciferase assay. Methods for applying the M2H assay at different rexinoid concentrations are further described for the determination of EC values for rexinoids from dose-response curves.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Clinical, Journal:  Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN. (Pubmed Central) -  Mar 31, 2020   
    These methods have been extensively applied beyond the present case study to generate several analogs of other potent RXR agonists (rexinoids), particularly the RXR agonist known as bexarotene (Bex), a Food and Drug Administration (FDA) approved drug for cutaneous T-cell lymphoma that is also often prescribed, off-label, for breast, lung, and other human cancers...Some of the more prominent examples include LGD100268, CD3254, and 9-cis-UAB30, to name only a few...For the synthesis of the modified base-structure analogs, often identical synthetic strategies used to access the base-structure are applied; however, reasonable alternative synthetic routes may need to be explored if the modified analog intermediates encounter bottlenecks where yields are negligible for a given step in the base-structure route. In fact, this particular problem was encountered and successfully resolved in our case study for generating an array of NEt-TMN analogs.
  • ||||||||||  UAB30 - UAB University / Birmingham
    Preclinical, Journal:  A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. (Pubmed Central) -  Jun 7, 2019   
    Both CD133-enriched and CD133-depleted medulloblastoma cell populations demonstrated sensitivity to UAB30, indicating its potential as a therapeutic option for group 3 medulloblastoma. The results of these studies suggest a potential therapeutic role for the low-toxicity synthetic retinoid X receptor selective agonist, UAB30, in RMS treatment.
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial initiation date, Trial primary completion date, IO biomarker:  Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov) -  Jan 3, 2018   
    P1,  N=40, Not yet recruiting, 
    Trial completion date: Mar 2020 --> Apr 2020 | Initiation date: Feb 2018 --> Mar 2018 Initiation date: Oct 2017 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Mar 2020
  • ||||||||||  UAB30 - UAB University / Birmingham
    Biomarker, Trial initiation date, Trial primary completion date, IO biomarker:  A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (clinicaltrials.gov) -  Nov 29, 2017   
    P1/2,  N=84, Not yet recruiting, 
    Initiation date: Oct 2017 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Mar 2020 Initiation date: Nov 2017 --> Feb 2018 | Trial primary completion date: Dec 2022 --> Aug 2022
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial completion:  Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers (clinicaltrials.gov) -  Dec 23, 2016   
    P1,  N=40, Completed, 
    Initiation date: Nov 2016 --> Oct 2017 Active, not recruiting --> Completed
  • ||||||||||  UAB30 - UAB University / Birmingham
    Enrollment closed, Trial initiation date:  Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers (clinicaltrials.gov) -  Aug 16, 2016   
    P1,  N=40, Active, not recruiting, 
    Active, not recruiting --> Completed Initiation date: Sep 2015 --> Aug 2013 | Recruiting --> Active, not recruiting
  • ||||||||||  UAB30 - UAB University / Birmingham
    Enrollment open, Trial initiation date, Trial primary completion date:  Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers (clinicaltrials.gov) -  Oct 22, 2015   
    P1,  N=40, Recruiting, 
    Initiation date: Sep 2015 --> Aug 2013 | Recruiting --> Active, not recruiting Terminated --> Recruiting | Initiation date: Aug 2013 --> Sep 2015 | Trial primary completion date: Sep 2014 --> Nov 2016
  • ||||||||||  UAB30 - UAB University / Birmingham
    Phase classification:  Study of 9cUAB30 in Healthy Participants (clinicaltrials.gov) -  Jun 18, 2015   
    P1,  N=15, Completed, 
    Terminated --> Recruiting | Initiation date: Aug 2013 --> Sep 2015 | Trial primary completion date: Sep 2014 --> Nov 2016 Phase classification: P=N/A --> P1
  • ||||||||||  UAB30 - UAB University / Birmingham
    Trial termination:  Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers (clinicaltrials.gov) -  Nov 25, 2014   
    P1,  N=40, Terminated, 
    Phase classification: P=N/A --> P1 Active, not recruiting --> Terminated
  • ||||||||||  UAB30 - UAB University / Birmingham
    Enrollment closed:  Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers (clinicaltrials.gov) -  Sep 19, 2014   
    P1,  N=40, Active, not recruiting, 
    Active, not recruiting --> Terminated Recruiting --> Active, not recruiting